Paolo Giorgio Arcidiacono
Overview
Explore the profile of Paolo Giorgio Arcidiacono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
225
Citations
2042
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanella G, Leone R, Frigo F, Rossi G, Zaccari P, Palumbo D, et al.
Gastrointest Endosc
. 2025 Jan;
PMID: 39842518
Background And Aims: Factors predicting the need for step-up procedures after EUS-guided drainage (EUS-FCD) of peripancreatic fluid collections (PFCs) were explored in retrospective studies restricted to Walled-Off Necrosis (WON) and...
2.
Rimini M, Foti S, Camera S, Rossari F, Vitiello F, Prinzi F, et al.
Oncology
. 2024 Dec;
1-22.
PMID: 39647475
Introduction: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy...
3.
Gentiluomo M, Corradi C, Apadula L, Comandatore A, Lauri G, Rossi G, et al.
Cancer
. 2024 Dec;
131(1):e35678.
PMID: 39639588
Background: Intraductal papillary mucinous neoplasms (IPMNs) are precursors to pancreatic cancer, but not all IPMNs progress to cancer. The objective of this study was to identify the germline genetic variants...
4.
Tacelli M, Partelli S, Falconi M, Arcidiacono P, Capurso G
United European Gastroenterol J
. 2024 Nov;
13(1):34-43.
PMID: 39540703
The incidence and prevalence of pancreatic neuroendocrine neoplasms are steadily increasing. These tumors are highly heterogeneous, with treatment options ranging from observation to surgery, and various medical therapies. The choice...
5.
Mangiavillano B, Ramai D, Kahaleh M, Tyberg A, Shahid H, Sarkar A, et al.
Endosc Int Open
. 2024 Oct;
12(10):C8.
PMID: 39450069
[This corrects the article DOI: 10.1055/a-2411-1814.].
6.
Mangiavillano B, Ramai D, Kahaleh M, Tyberg A, Shahid H, Sarkar A, et al.
Endosc Int Open
. 2024 Oct;
12(10):E1143-E1149.
PMID: 39398449
Although outcomes of lumen-apposing metal stents (LAMS) placement in native anatomy have been reported, data on LAMS placement in surgically altered anatomy (SAA) are sparse. We aimed to assess outcomes...
7.
Vanella G, Leone R, Frigo F, Bronswijk M, van Wanrooij R, Tamburrino D, et al.
DEN Open
. 2024 Oct;
5(1):e70024.
PMID: 39377069
Objectives: Malignant double obstruction, defined as the simultaneous presence of biliary and gastric outlet obstruction, represents a challenging clinical scenario. Previous retrospective experiences have demonstrated shorter dysfunction-free survival (DyFS) of...
8.
Galvez-Montosa F, Peduzzi G, Sanchez-Maldonado J, Ter Horst R, Cabrera-Serrano A, Gentiluomo M, et al.
Int J Cancer
. 2024 Sep;
156(2):339-352.
PMID: 39319538
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with patients having unresectable or metastatic disease at diagnosis, with poor prognosis and very short survival. Given that genetic...
9.
Marzioni M, Crino S, Lisotti A, Fuccio L, Vanella G, Amato A, et al.
Surg Endosc
. 2024 Sep;
38(11):6207-6226.
PMID: 39317905
Background: Malignant Distal Biliary Obstruction (MBDO) is a common event occurring along the natural history of both pancreatic cancer and cholangiocarcinoma. Epidemiological and biological features make MBDO one of the...
10.
Lauri G, Archibugi L, Arcidiacono P, Repici A, Hassan C, Capurso G, et al.
Dig Liver Dis
. 2024 Sep;
56(12):2004-2010.
PMID: 39277511
Background: The effectiveness of various primary upfront drainage techniques for distal malignant biliary obstructions (dMBO) is not well-established. Objective: To compare the technical and clinical success rates and adverse event...